Page 1 of 2
`
`For Consumers
`
`(/)
`
`Text size A- A+
`
`Search...
`
`Learn More
`
`Patient Assistance
`Program
`(/Portals/77/-/m/BL/United%
`20States/Files/Downloads/ECP/
`
`Savings
`
`(http://bauschaccessprogram.com/)
`
`<
`
`United States
`
`Home (/ecp/)
`
`Newsroom (/our-
`company/recent-news/)
`
`(/ecp/)
`
`Worldwide Locations
`Careers (/our-
`(/our-
`company/careers/)
`company/worldwide-
`Online Ordering
`For Your Practice
`Clinical Resources
`Our Products
`(http://www.bausch.com/ecp/Our-(http://www.bausch.com/ecp/Clinical-(http://www.bausch.com/ecp/For-(http://www.bausch.com/ecp/Online-
`
`
`
`locations/)
`Your-Practice)
`Products)
`Resources)
`Ordering)
`Home (/ecp/)
`... Rx Pharmaceuticals (http://www.bausch.com/ecp/Our-Products/Rx-Pharmaceuticals) Rx
`Pharmaceuticals (http://www.bausch.com/ecp/Our-Products/Rx-Pharmaceuticals/Rx-Pharmaceuticals) Alrex (Loteprednol
`Etabonate Ophthalmic Suspension 0.2%) (Http://Www.bausch.com/Ecp/Our-Products/Rx-Pharmaceuticals/Rx-
`Pharmaceuticals/Alrex-Loteprednol-Etabonate-Ophthalmic-Suspension-02)
`
`Alrex (loteprednol etabonate ophthalmic suspension) 0.2%
`
`Alrex ophthalmic suspension (loteprednol etabonate ophthalmic suspension) 0.2%
`is indicated for temporary relief of the signs and symptoms of seasonal allergic
`conjunctivitis.
`1
`
`Alrex contains a C-20 ester corticosteroid that covers many inflammatory mediators
`of the ocular allergic cascade.* Common signs and symptoms that are associated
`with inflamed seasonal allergic conjunctivitis include: itching, tearing, burning,
`redness, foreign-body sensation, and discomfort.
`2
`*There is no generally accepted explanation for the mechanism of action of ocular
`corticosteroids.
`
`INDICATION
`Alrex (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of
`seasonal allergic conjunctivitis.
`IMPORTANT SAFETY INFORMATION
`• Alrex is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis
`(dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular
`structures. Alrex is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of
`this preparation and to other corticosteroids.
`
`• Prolonged use of Alrex is associated with several warnings and precautions, including glaucoma with optic nerve damage,
`defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular
`infections (including herpes simplex), delay in wound healing and increase in bleb formation.
`
`• If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal
`of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid
`of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
`
`• Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% -
`0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora,
`foreign body sensation, itching, injection, and photophobia.
`Click here (/Portals/77/-/m/BL/United States/Files/Package Inserts/Pharma/alrex-package-insert.pdf?ver=2017-06-16-
`091104-867) for full Prescribing Information for Alrex.
`
`1. Alrex [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013.
`2. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol.
`2008;92(4):455-459.
`
`ALX.0037.USA.17
`
`Professional Resources
`Meetings and Exhibits
`(/ecp/for-your-
`practice/professional-
`calendar/meetings-and-
`exhibits/)
`Educational Meetings/Dinners
`(/ecp/for-your-
`practice/professional-
`calendar/education/)
`Resource Materials (/ecp/for-
`your-practice/resource-
`materials/)
`Training & Tools (/ecp/for-your-
`practice/training/)
`
`Products
`Online Ordering (/ecp/online-
`ordering/online-ordering-
`overview/)
`Contact Lenses (/ecp/our-
`products/contact-lenses)
`Contact Lens Care (/ecp/our-
`products/contact-lens-care/)
`OTC Ophthalmics (/ecp/our-
`products/otc-ophthalmics/)
`Eye Vitamins (/ecp/our-
`products/eye-vitamins)
`Rx Pharmaceuticals (/ecp/our-
`products/rx-
`pharmaceuticals/rx-
`pharmaceuticals-ecp/)
`© 2017 Bausch & Lomb Incorporated.
`
`Customer Support
`Worldwide Locations (/our-
`company/worldwide-locations)
`Customer policies and forms
`(/reference/customer-policies-
`and-forms/)
`Customer Commitment &
`Partnership (/ecp/for-your-
`practice/resource-
`materials/customer-
`commitment-and-partnership)
`
`Legal
`Legal Notice (/reference/legal-
`notice/)
`Privacy Policy
`(/reference/privacy-policy/)
`Safety Data Sheets (SDS)
`(/ecp/for-your-
`practice/resource-
`materials/material-safety-data-
`sheets)
`
`Newsroom (/our-
`company/recent-news/)
`Careers (/our-
`company/careers/)
`Investor Relations (/our-
`company/investor-relations/)
`Grants & Contributions (/our-
`company/grants-and-
`charitable-contributions/grants-
`and-charitable-contributions-
`landing)
`
`http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/alrex-loteprednol-etabonate-ophthalmic-suspension-02
`
`MYLAN - EXHIBIT 1089
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`
`
`For Consumers
`
`(/)
`
`Text size A- A+
`
`Search...
`
`Learn More
`
`Patient Assistance
`Program
`(/Portals/77/-/m/BL/United%
`20States/Files/Downloads/ECP/
`
`Savings
`
`(http://bauschaccessprogram.com/)
`
`<
`
`United States
`
`Home (/ecp/)
`
`Newsroom (/our-
`company/recent-news/)
`
`(/ecp/)
`
`Worldwide Locations
`Careers (/our-
`(/our-
`company/careers/)
`company/worldwide-
`Online Ordering
`For Your Practice
`Clinical Resources
`Our Products
`(http://www.bausch.com/ecp/Our-(http://www.bausch.com/ecp/Clinical-(http://www.bausch.com/ecp/For-(http://www.bausch.com/ecp/Online-
`
`
`
`locations/)
`Your-Practice)
`Products)
`Resources)
`Ordering)
`Home (/ecp/)
`... Rx Pharmaceuticals (http://www.bausch.com/ecp/Our-Products/Rx-Pharmaceuticals) Rx
`Pharmaceuticals (http://www.bausch.com/ecp/Our-Products/Rx-Pharmaceuticals/Rx-Pharmaceuticals) Alrex (Loteprednol
`Etabonate Ophthalmic Suspension 0.2%) (Http://Www.bausch.com/Ecp/Our-Products/Rx-Pharmaceuticals/Rx-
`Pharmaceuticals/Alrex-Loteprednol-Etabonate-Ophthalmic-Suspension-02)
`
`Alrex (loteprednol etabonate ophthalmic suspension) 0.2%
`
`Alrex ophthalmic suspension (loteprednol etabonate ophthalmic suspension) 0.2%
`is indicated for temporary relief of the signs and symptoms of seasonal allergic
`conjunctivitis.
`1
`
`Alrex contains a C-20 ester corticosteroid that covers many inflammatory mediators
`of the ocular allergic cascade.* Common signs and symptoms that are associated
`with inflamed seasonal allergic conjunctivitis include: itching, tearing, burning,
`redness, foreign-body sensation, and discomfort.
`2
`*There is no generally accepted explanation for the mechanism of action of ocular
`corticosteroids.
`
`INDICATION
`Alrex (loteprednol etabonate ophthalmic suspension) 0.2% is indicated for the temporary relief of the signs and symptoms of
`seasonal allergic conjunctivitis.
`IMPORTANT SAFETY INFORMATION
`• Alrex is contraindicated in most viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis
`(dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal diseases of the ocular
`structures. Alrex is also contraindicated in individuals with known or suspected hypersensitivity to any of the ingredients of
`this preparation and to other corticosteroids.
`
`• Prolonged use of Alrex is associated with several warnings and precautions, including glaucoma with optic nerve damage,
`defects in visual acuity, cataract formation, secondary ocular infections, exacerbation or prolongation of viral ocular
`infections (including herpes simplex), delay in wound healing and increase in bleb formation.
`
`• If this product is used for 10 days or longer, intraocular pressure should be monitored. The initial prescription and renewal
`of the medication order beyond 14 days should be made by a physician only after reexamination of the patient with the aid
`of magnification. Fungal infections of the cornea may develop with prolonged use of corticosteroids.
`
`• Ocular adverse reactions occurring in 5-15% of patients treated with loteprednol etabonate ophthalmic suspension (0.2% -
`0.5%) in clinical studies included abnormal vision/blurring, burning on instillation, chemosis, discharge, dry eyes, epiphora,
`foreign body sensation, itching, injection, and photophobia.
`Click here (/Portals/77/-/m/BL/United States/Files/Package Inserts/Pharma/alrex-package-insert.pdf?ver=2017-06-16-
`091104-867) for full Prescribing Information for Alrex.
`
`1. Alrex [package insert]. Tampa, FL: Bausch & Lomb Incorporated; 2013.
`2. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol.
`2008;92(4):455-459.
`
`ALX.0037.USA.17
`
`Professional Resources
`Meetings and Exhibits
`(/ecp/for-your-
`practice/professional-
`calendar/meetings-and-
`exhibits/)
`Educational Meetings/Dinners
`(/ecp/for-your-
`practice/professional-
`calendar/education/)
`Resource Materials (/ecp/for-
`your-practice/resource-
`materials/)
`Training & Tools (/ecp/for-your-
`practice/training/)
`
`Products
`Online Ordering (/ecp/online-
`ordering/online-ordering-
`overview/)
`Contact Lenses (/ecp/our-
`products/contact-lenses)
`Contact Lens Care (/ecp/our-
`products/contact-lens-care/)
`OTC Ophthalmics (/ecp/our-
`products/otc-ophthalmics/)
`Eye Vitamins (/ecp/our-
`products/eye-vitamins)
`Rx Pharmaceuticals (/ecp/our-
`products/rx-
`pharmaceuticals/rx-
`pharmaceuticals-ecp/)
`© 2017 Bausch & Lomb Incorporated.
`
`Customer Support
`Worldwide Locations (/our-
`company/worldwide-locations)
`Customer policies and forms
`(/reference/customer-policies-
`and-forms/)
`Customer Commitment &
`Partnership (/ecp/for-your-
`practice/resource-
`materials/customer-
`commitment-and-partnership)
`
`Legal
`Legal Notice (/reference/legal-
`notice/)
`Privacy Policy
`(/reference/privacy-policy/)
`Safety Data Sheets (SDS)
`(/ecp/for-your-
`practice/resource-
`materials/material-safety-data-
`sheets)
`
`Newsroom (/our-
`company/recent-news/)
`Careers (/our-
`company/careers/)
`Investor Relations (/our-
`company/investor-relations/)
`Grants & Contributions (/our-
`company/grants-and-
`charitable-contributions/grants-
`and-charitable-contributions-
`landing)
`
`http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/alrex-loteprednol-etabonate-ophthalmic-suspension-02
`
`MYLAN - EXHIBIT 1089
`Mylan Pharmaceuticals Inc. et al. v. Allergan, Inc.
`IPR2016-01127, -01128, -01129, -01130, -01131, & -01132
`
`
`
`All information and materials on this site pertain to the U.S. only, unless otherwise indicated.
`Orthokeratology (/ecp/our-
`products/orthokeratology)
`Cataract Surgery (/ecp/our
`
`
`
`Page 2 of 2
`
`
`
`
`
`http://www.bausch.com/ecp/our-products/rx-pharmaceuticals/rx-pharmaceuticals/alrex-loteprednol-etabonate-ophthalmic-suspension-02
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
